Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Breast Neoplasms 7 Lung Neoplasms 6 Carcinoma, Non-Small-Cell Lung 5 Ovarian Neoplasms 4 Multiple Myeloma 4 Lymphoma 4 Endometrial Neoplasms 3 Carcinoma, Hepatocellular 3 Urinary Bladder Neoplasms 2 Triple Negative Breast Neoplasms 2 Thyroid Neoplasms 2 Neoplasm Metastasis 2 Hereditary Sensory and Autonomic Neuropathies 2 Hematologic Neoplasms 2 Glioblastoma 2 Fallopian Tube Neoplasms 2 Carcinoma, Transitional Cell 2 Carcinoma, Renal Cell 2 Advanced Nonhematologic Malignancies 2 Waldenstrom Macroglobulinemia 1 Uterine Neoplasms 1 Uterine Cervical Neoplasms 1 Thyroid Carcinoma, Anaplastic 1 Stomach Neoplasms 1 Somatostatinoma 1 Sarcoma, Synovial 1 Sarcoma 1 Recurrent Malignant Solid Neoplasm 1 Recurrent Lung Squamous Cell Carcinoma 1 Recurrence 1

Interventions

Doxorubicin 142 Ifosfamide 85 Radiotherapy 82 Cyclophosphamide 72 Gemcitabine 63 Filgrastim 54 pembrolizumab 43 pazopanib 40 Etoposide 39 Docetaxel 39 Vincristine 37 Trabectedin 37 Cisplatin 35 Nivolumab 32 Magnetic Resonance Spectroscopy 26 Irinotecan 26 Carboplatin 25 Surgical Procedures, Operative 24 Temozolomide 23 Radiation 22 Ipilimumab 22 Bevacizumab 20 Blood Specimen Collection 19 Granulocyte Colony-Stimulating Factor 18 Biopsy 18 eribulin 17 anlotinib 17 Sirolimus 17 Mesna 17 Melphalan 17

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Sarcoma × sapanisertib × Clear all

NCT02987959 2022-10-14

Study of TAK-228 (MLN0128) in Soft Tissue Sarcomas

Fox Chase Cancer Center

Phase 2 Terminated

6 enrolled 10 charts

Sarcoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡